ADC Therapeutics SA: Q2 2024 Financial Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2024, for ADC Therapeutics SA, a commercial-stage biopharmaceutical company focused on antibody drug conjugates (ADCs). The Company's primary revenue source is its flagship product, ZYNLONTA, approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company operates as a single segment and is classified as an accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $17,410 | $19,283 | $35,463 | $38,275 |
| Net Loss | $(36,544) | $(48,922) | $(83,150) | $(108,296) |
| Net Loss Per Share (Basic/Diluted) | $(0.38) | $(0.60) | $(0.93) | $(1.33) |
| Operating Expenses | $(46,451) | $(58,932) | $(98,117) | $(128,134) |
| Cash and Cash Equivalents (End of Period) | $300,119 | $347,510 | $300,119 | $347,510 |
| Senior Secured Term Loans | $113,673 | $112,730 | $113,673 | $112,730 |
| Deferred Royalty Obligation | $316,211 | $303,572 | $316,211 | $303,572 |
Note: Revenue consists primarily of product sales ($17.0M in Q2) and license/royalty income ($0.4M in Q2). Operating expenses include R&D ($24.3M), Selling & Marketing ($10.7M), and G&A ($10.2M).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 9.7% in Q2 2024 compared to Q2 2023, driven primarily by a 11.3% decrease in product sales volume, partially offset by higher selling prices. Gross-to-net (GTN) deductions, specifically discarded drug rebates, increased as a percentage of gross sales.
- Expense Reductions: Total operating expenses decreased 21.2% year-over-year. R&D expenses dropped 22.5% due to the discontinuation of the Cami program, lower clinical trial costs for ZYNLONTA, and portfolio prioritization. Selling and marketing expenses fell 26.0% due to reduced headcount and lower marketing spend.
- Improved Net Loss: Net loss improved by 25.3% to $36.5 million, reflecting the significant reduction in operating costs.
- Financing Activity: In May 2024, the Company completed an underwritten equity offering raising approximately $97.4 million in net proceeds, significantly bolstering liquidity.
Outlook, Risks, and Management Commentary
- Liquidity: Management stated that as of June 30, 2024, cash and cash equivalents of $300.1 million are sufficient to fund operations for at least the next 12 months. There is no substantial doubt regarding the Company's ability to continue as a going concern.
- Pipeline Updates:
- LOTIS-7: Dose escalation completed for ZYNLONTA in combination with bispecific antibodies (glofitamab or mosunetuzumab) in relapsed/refractory B-cell non-Hodgkin lymphoma. No dose-limiting toxicities were observed.
- MZL Data: Investigator-initiated trial data for ZYNLONTA in Marginal Zone Lymphoma showed high complete response rates (13 of 15 evaluable patients).
- Solid Tumors: IND-enabling studies are progressing for Claudin-6 and NaPi2b targets; PSMA and ASCT2 candidates are in selection stages.
- Risks and Contingencies:
- Debt Obligations: The Company carries significant debt, including a senior secured term loan (effective interest rate 16.83%) and a deferred royalty obligation with HealthCare Royalty Management (HCR). The HCR agreement limits cash generation from ZYNLONTA sales and may impact attractiveness as an acquisition target.
- Regulatory and Clinical: Risks include the timing and outcome of clinical trials, regulatory approvals, and the ability to commercialize products successfully.
- Investor Litigation: Shareholder suits are subject to exclusive jurisdiction in Switzerland, which may impose additional costs on shareholders.
Key Facts for Investor Verification
- Cash Runway: Verify the sustainability of the $300.1 million cash balance against the burn rate, considering the high interest expense on the senior secured term loan and the accretion of the deferred royalty obligation.
- Revenue Quality: Monitor the trend of Gross-to-Net (GTN) adjustments, specifically discarded drug rebates, which are increasing as a percentage of gross sales and impacting net revenue.
- Debt Covenants: Review the restrictive covenants associated with the Loan Agreement with Oaktree/Owl Rock and the HCR royalty agreement to understand potential limitations on future financing or strategic options.
- Clinical Catalysts: Track the enrollment and data readouts for the LOTIS-7 combination trial and the MZL investigator-initiated trial, as these are critical for expanding the ZYNLONTA market opportunity.
- Equity Dilution: Note the recent issuance of 13.4 million shares and 8.2 million pre-funded warrants in May 2024, which increased the share count and may impact future per-share metrics.